Friday 6 November 2026
Export BRKR’s income statement to Excel — free account
Bruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
- Revenue
- +1.57%
- EPS
- −75.4%
- Free cash flow
- +278.7%
- Total debt
- −14.7%
Quarter to September 2026, against a year earlier
61.20
3.14
+5.41%
Follow BRKR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.08 | 1.59 | 2.62 | 2.81 | |
P/FCF ratio |
105.01 | 72.24 | 77.21 | 36.64 | |
P/Operating CF |
31.12 | 77.21 | (118.42) | 83.54 | |
P/B ratio |
2.89 | 2.23 | 3.82 | 4.11 | |
Price to Tangible BV |
272.95 | 0.00 | 89.33 | 0.00 | |
EV/Sales |
2.54 | 2.03 | 3.09 | 3.26 | |
EV/EBITDA |
30.23 | 25.60 | 54.16 | 72.26 | |
EV/Operating CF |
65.04 | 50.15 | 56.75 | 33.55 | |
EV/FCF |
128.07 | 92.45 | 91.03 | 42.55 | |
Quick Ratio |
0.66 | 0.50 | 0.61 | 0.58 | |
Current Ratio |
1.73 | 1.55 | 1.85 | 1.84 | |
Net Debt/EBITDA |
11.68 | 22.45 | (224.64) | 0.00 | |
Debt/Assets |
29.95% | 27.26% | 30.15% | 29.40% | |
Debt/Equity |
0.76 | 0.68 | 0.76 | 0.74 | |
Asset Turnover |
0.57 | 0.57 | 0.56 | 0.57 | |
Operating CF/Net income |
15.42 | 20.34 | 1.23 | (0.96) | |
Capex/Depreciation |
(0.39) | (0.42) | (0.50) | (0.40) | |
Research and Development Expense of Revenue |
10.19% | 12.30% | 11.25% | 10.53% | |
Selling, General and Administrative Expense of Revenue |
25.30% | 29.40% | 28.49% | 25.92% | |
Intangible Assets out of Total Assets |
0.39 | 0.40 | 0.38 | 0.51 | |
Share Based Compensation of Revenue |
2.07% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.22) | (0.28) | (0.16) | (0.14) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.32%) | (0.66%) | (1.16%) | (1.56%) | |
Free Cash Flow Yield |
0.95% | 1.38% | 1.30% | 2.73% | |
Revenue per Share |
6.44 | 5.41 | 5.51 | 5.73 | |
Operating CF per Share |
1.51 | 0.47 | (0.51) | 0.78 | |
Capex per Share |
(0.15) | (0.16) | (0.19) | (0.14) | |
Free Cash Flow per Share |
1.37 | 0.31 | (0.70) | 0.63 | |
Cash per Share |
1.97 | 0.88 | 1.21 | 0.78 | |
Shareholders Equity per Share |
16.29 | 16.21 | 15.76 | 15.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.29 | 16.21 | 15.76 | 15.12 | |
Free Cash Flow |
207.20 | 47.00 | (106.20) | 96.70 | |
Working Capital |
933.30 | 748.50 | 1,020.30 | 985.00 | |
Capital Expenditures |
(22.60) | (24.20) | (28.80) | (21.50) | |
Net Current Asset Value |
(1,555.40) | (1,560.10) | (1,427.70) | (1,365.20) | |
EV/EBIT |
127.88 | 150.97 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.02 | |
Price to Operating Income |
104.86 | 117.97 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
555.20 | 540.25 | 534.25 | 557.40 | |
Average Payables |
225.00 | 256.85 | 221.60 | 196.10 | |
Average Inventory |
1,081.20 | 1,119.00 | 1,169.20 | 1,149.65 | |
Average Assets |
6,024.05 | 6,031.90 | 6,196.35 | 6,131.60 | |
Average Common Equity |
2,135.30 | 2,149.95 | 2,109.80 | 2,377.75 |
Columns are period end dates · fundamentals updated 5 Nov 2026